The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
about
The Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseMiddle East respiratory syndrome: obstacles and prospects for vaccine developmentDrivers of Inter-individual Variation in Dengue Viral Load DynamicsIdentifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus SpeciesDengue: knowledge gaps, unmet needs, and research prioritiesPatterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strainHuman CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificityIdentification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cellsIn a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccinationCD4+ and CD8+ T-cell immunity to Dengue - lessons for the study of Zika virus.An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer ModelingCD8+ T lymphocyte expansion, proliferation and activation in dengue fever.Dengue Virus NS Proteins Inhibit RIG-I/MAVS Signaling by Blocking TBK1/IRF3 Phosphorylation: Dengue Virus Serotype 1 NS4A Is a Unique Interferon-Regulating Virulence Determinant.CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets.Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in miceLicensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection.T cell immunity to dengue virus and implications for vaccine design.Immune correlates of protection for dengue: State of the art and research agenda.A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Enhancing vaccine effectiveness with delivery technology.Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen.A Tetravalent Formulation Based on Recombinant Nucleocapsid-like Particles from Dengue Viruses Induces a Functional Immune Response in Mice and Monkeys.Vaccines licensed and in clinical trials for the prevention of dengue.Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Development of Peptide Vaccines in Dengue.Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans.How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?In silico design of a Zika virus non-structural protein 5 aiming vaccine protection against zika and dengue in different human populations.Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.Immune Response to Dengue and Zika.Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development.Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B.
P2860
Q26995782-199E5133-247F-4D88-90A8-B31315ED3DD7Q27013314-C8876136-88CF-4562-BFD7-5C7AAD1B5DF5Q27882968-7146CE3B-5F88-49A7-BE4D-478B80A5A80AQ28119651-74E274C2-AC1C-4403-BCC2-032B897FDD71Q28729764-FF9EFB23-E6CB-4E75-BAB8-78F24DE4F6D7Q28729784-43FB5678-F382-4858-9F23-42FA3C89BD30Q28733418-A05A75A4-C131-4D01-B255-C47ACF4FC878Q28950660-DD20DCBD-ED9C-4E90-A1DA-941D411D55E9Q30250977-14E26EAC-9022-4C44-A23F-C671CE03F5FDQ30394327-7AA09E45-A149-4678-9BA6-265DB4949679Q33780548-DD0CEDFB-85EA-49C0-B116-FC34E96027FBQ35078921-6140F567-6C8B-4DE7-A506-EF97E228FBC7Q35620170-4474C8FC-307C-42E0-B689-4FD8E2767CC2Q36208591-530C0BF4-660A-4F71-AF77-6A449C4FE7FCQ36250195-EDF40493-F550-4742-B6A7-3A96E1AF266CQ36263779-92309CC4-0462-4A32-8B1F-BF51793B1773Q37115807-CE91FD64-5848-4F44-9BAD-DF222381407AQ37137235-8DF53E8B-3B7C-4046-98B0-5AB5938FBBDCQ37336555-B5B0F345-6865-48D1-9076-C832796E9362Q37604714-E92C9FE8-AEC2-4D15-90F8-80DF59FFB5F7Q38631171-7A8A50E3-DDC0-493E-A061-F02AE463F6BEQ38652971-1C4F623F-476B-44B6-A771-96EA235ED09EQ38658737-C540AF09-98C9-4CE8-97A5-00A40CF2AE27Q38765636-FEA3E771-C808-4D60-B8FF-66119BB47139Q38871575-1A5AE8D9-F274-4E29-B6F6-02C5ED5AE0EDQ39023333-8ED39C44-C2EF-442A-83AD-3A859D9B6EC7Q39172722-BB164728-093B-40B6-BFA4-13B248705CC8Q39535403-EDBDA1DD-244F-4ED1-822C-D032284CF1FFQ40038715-8F9A802C-21C3-4593-9880-3A44D8C461E8Q40047603-A538FC6F-B1C1-41F4-8B5E-AB59CFFDDA22Q40109446-F7F71D00-858C-468E-9638-28CD1D0807DEQ41924182-D2200A83-7A1B-4002-BBA0-EB3CD4185272Q41928044-7CE2F217-C2FD-4444-9ECD-8C65CA338848Q45324353-6155118A-76EF-410C-89A6-28B468F8B4C6Q47265866-B0601A39-D188-4504-AC2C-79042BE2CC1AQ47551925-E1AE812F-BB0B-4A70-A591-67042735011EQ47558465-F447A317-CD6B-43F4-A7CC-6383590D8644Q47562022-65710D38-AC7D-4073-9548-014A75F72985Q51336680-4601DD25-A124-476E-AEAF-EFC8AACF9D68Q55342452-E804B87E-7AAC-4906-98C3-B082F75FC7C5
P2860
The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The human CD8+ T cell response ...... nst highly conserved epitopes.
@ast
The human CD8+ T cell response ...... nst highly conserved epitopes.
@en
The human CD8+ T cell response ...... nst highly conserved epitopes.
@nl
type
label
The human CD8+ T cell response ...... nst highly conserved epitopes.
@ast
The human CD8+ T cell response ...... nst highly conserved epitopes.
@en
The human CD8+ T cell response ...... nst highly conserved epitopes.
@nl
prefLabel
The human CD8+ T cell response ...... nst highly conserved epitopes.
@ast
The human CD8+ T cell response ...... nst highly conserved epitopes.
@en
The human CD8+ T cell response ...... nst highly conserved epitopes.
@nl
P2093
P2860
P50
P356
P1433
P1476
The human CD8+ T cell response ...... nst highly conserved epitopes.
@en
P2093
Aruna D de Silva
Beth Kirkpatrick
Derek J Bangs
John Sidney
Michael A Angelo
P2860
P304
P356
10.1128/JVI.02129-14
P407
P50
P577
2014-10-15T00:00:00Z